Other languages Connect Biopharma Holdings Limited

Equities

CNTB

US2075231017

Market Closed - Nasdaq Other stock markets 02:00:00 04/05/2024 am IST			5-day change	1st Jan Change
1.59 ^USD	+2.58%		+18.66%	+34.75%

17/04	Sector Update: Health Care Stocks Retreating Late Afternoon	MT
17/04	Sector Update: Health Care	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Connect Biopharma Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	17/04
Connect Biopharma Holdings Limited Appoints James Huang to Board of Directors	13/02
Connect Biopharma Holdings Limited Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-To-Severe Persistent Asthma	12/12
Simcere Pharmaceutical Group Limited Enters into an Exclusive License and Collaboration Agreement with Connect Biopharma Hongkong Limited in Relation to Rademikibart	21/11
Connect Biopharma Releases 'Positive' Stage 2 Atopic Dermatitis Trial Results; Unveils Licensing Deal; Shares Surge Premarket	21/11
Connect Biopharma Holdings Limited Appoints Kan Chen as Member of Compensation Committee	21/11
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-To-Severe Atopic Dermatitis	21/11
Connect Biopharma Holdings Limited Announces Resignation of Derek DiRocco as a Director	21/23/21
Connect Biopharma Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023	13/23/13
Connect Biopharma Holdings Limited Presents Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology	10/23/10
Top Premarket Gainers	02/23/02
Connect Biopharma Holdings Limited Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis	02/23/02
Connect Biopharma Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2022	12/23/12
Connect Biopharma Holdings Limited Announces CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions	18/23/18
Top Premarket Decliners	23/23/23
Connect Biopharma Provides Business and Clinical Development Program Update	30/22/30
Connect Biopharma Receives Nasdaq Non-Compliance Notice	05/22/05
Connect Biopharma Says CBP-201 Met All Primary, Key Secondary Endpoints in Atopic Dermatitis Trial in China	04/22/04
Connect Biopharma Holdings Limited Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China	04/22/04
Connect Biopharma Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2022	14/22/14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Connect Biopharma Holdings Limited

Equities

CNTB

US2075231017

Other languages

Filters